RxDoctor Payments Data

Robert Greenhagen, DPM

Foot & Ankle Surgery · Omaha, NENPI 1649433848

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $19,102 of the $28,998 with a category attached, or 65.9%. Stryker accounts for 81.5% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2023 at $7,147 and has fallen 58.1% since, to $2,994 in 2025.

$28,998in general payments, 2019–2025

Across 487 payments — averaging $59.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$24K
  • Smith+Nephew$4K
  • Abbott$173
  • Osiris Therapeutics Inc.$135
  • GRT US Holding, Inc.$88
  • Amgen$87
  • plus $958 from 22 others

What the payments were for

  • Speaking & faculty fees$9633%
  • Travel & lodging$8,93331%
  • Food & beverage$19,10266%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,998 in reported general payments places this provider in the 85th percentile of 43 foot & ankle surgery providers in Nebraska.

See all foot & ankle surgery providers in Nebraska

Medicare billing

Part B allowed, 2024
$742,957
Medicare patients
366
Services billed
2,726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ketoconazole30$1,828
Gabapentin77$1,439
Pregabalin19$832
Ondansetron OdtOndansetron11$171

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →